Biohit Oyj - Decisions of general meeting

Resolutions of the Annual General Meeting of Biohit Oyj

Biohit Oyj     Stock exchange release   11.4.2012     6.30 pm

The Annual General Meeting (AGM) of Biohit Oyj held on Wednesday 11 April 2012
approved the financial statements of the parent company and the consolidated
financial statements, and discharged the members of the Board of Directors and
the President and CEO from liability for the financial year 2011. 


Distribution of dividends

In accordance with the proposal by the Board of Directors, the AGM decided that
the profit for the financial period ended on 31 December 2011 will be recorded
in the profit and loss account. 

  In accordance with the proposal by the Board of Directors, the AGM decided
that on the basis of the financial statements to be adopted for the financial
period ended on 31 December 2011, a dividend of EUR 0.1973 per each A share and
EUR 0.2007 for each B share be paid. Dividend will be paid to shareholders
recorded in the company's shareholder register on the matching day, 16 April
2012. The Board of Directors proposes that the dividend will be paid out on 23
April 2012. 

  In accordance with the proposal of the Board of Directors, the AGM decided
that on the basis of the financial statements to be adopted for the financial
period ended on 31 December 2011, funds from the invested non-restricted equity
fund be distributed to shareholders as a capital repayment, with the capital
repaid amounting to EUR 0.80 for each A and B share. Capital will be repaid to
shareholders recorded in the company's shareholder register on the repayment
day, 16 April 2012. The Board of Directors proposes that the capital repayment
will be made on 23 April 2012. 


Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be
seven (7). Furthermore, that the following Board members re-elected until the
end of the next AGM: Kalle Kettunen, M.Sc.Eng., Osmo Suovaniemi, professor,
Mikko Salaspuro, professor, Eero Lehti, M.Sc (Sos.Sc), Member of Parliament,
Petteri Kilpinen, CEO, Seppo Luode, M.Sc.Eng., and Saila Miettinen-Lähde, CFO 


Additionally, the AGM decided that the chairman of the Board of Directors would
be paid a monthly fee of EUR 1,600 and the ordinary members would be paid a
monthly fee of EUR 1,500. 

Auditors

The AGM elected authorised public accountants Ernst & Young Oy as the company's
auditors, with APA Erkka Talvinko as the head auditor, until the end of the
next AGM. 



All decisions of the AGM were made unanimously. The minutes of the AGM will be
available for review by shareholders by 16 April 2012 on the company's website
(www.biohithealthcare.com/investors) and at the corporate headquarters of
Biohit, located at Laippatie 1, 00880 Helsinki. 



Further information:

Semi Korpela, M.Sc. (Econ.)
CEO, Biohit Group
Tel.: +358 9 773 861

Mobile: +358 40 573 7701
semi.korpela@biohit.fi

BIOHIT HealthCare

Innovating for Health

Cancer Prevention



Distribution:

NASDAQ

OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohithealthcare.com



About Biohit

Biohit Oyj is a globally operating Finnish biotechnology company established in
1988. Biohit's mission crystallizes in its motto “Innovating for Health”. The
company assumes social responsibility by producing innovations, new
technologies and analysis systems for use in medicine, research institutions
and industry. These products help to promote research and diagnostics, while
improving quality of life by preventing disease, human suffering and financial
loss. Biohit also seeks to innovate and develop the marketing and availability
of its products and services. 

Biohit works with scientific communities to produce new technologies, products
and services based on research results and innovations. These can be used to
develop safe and cost-effective diagnostic tests for the early detection and
prevention of diseases of the gastrointestinal tract. (www.biohithealthcare.com
/ International / State of the art GastroPanel and Acetium innovations for the
unmet need). 

In January 2012, sixteen world-leading gastroenterology specialists from eleven
countries proposed in their SJG publication the use of the biomarkers of the
modern GastroPanel test for safe and cost-efficient primary diagnosis and
screening of Helicobacter infection and atrophic gastritis in patients with
stomach discomfort and in asymptomatic patients, as it is neither safe nor
cost-efficient to use the 13C urea breath test for this purpose. In addition,
the authors of the publication state that acetaldehyde generated in an
achlorhydric stomach (a consequence of atrophic gastritis) is a significant
reason for an increased gastric and oesophageal cancer risk.  Acetium capsules
can reduce the amount of cancer-causing acetaldehyde generated in the stomach -
and thus, very likely, they also reduce the cancer risk (SJG: “GastroPanel
biomarkers: Rationale in diagnosis and screening of atrophic gastritis with
stomach-specific plasma biomarkers”, Scandinavian Journal of Gastroenterology.
2012; 47: 136-147). 

Biohit's products include analysis systems for the prevention and early
diagnosis of gastrointestinal diseases, such as the blood-sample based
GastroPanel examinations for the diagnosis of stomach illnesses and associated
risks, quick tests for the diagnosis of lactose intolerance and H. pylori
infection in connection with gastroscopy, and the ColonView examination for the
early detection of intestinal bleeding that indicates a risk